About this Research Topic
The aim of this Research Topic is to provide an overview of the new advances in the diagnostic and treatment approaches for canine melanoma in comparative oncology, with a focus on research that has been translated from or can be translated to human melanoma patients.
Canine and human melanoma share numerous biological and molecular features. In both species, malignant melanoma (MM) is a highly aggressive tumor of skin and mucosae. Similar to human MM, canine MM is often associated with an aggressive malignant behavior with rapid invasion of surrounding normal tissues, frequent metastasis and resistance to therapy. Despite numerous advances in the diagnostic and treatment options, MM remains fatal in most of the cases. For this reason, there is currently an urgent need to better understand genetic and molecular mechanisms driving melanoma development and progression, as well as find valuable new prognostic biomarkers, and novel, effective therapeutic approaches to improve rate of patient survival.
Submissions that focus on new melanoma diagnosis measures, able to allow an early detection of the tumor, helping in the distinction between benign and malignant cases, recognition of metastatic patients, are highly encouraged. In addition, results on treatment of canine melanoma with new therapeutic approaches exploiting immune- or targeted therapy are welcomed. Finally, studies shedding light on the molecular and biological pathways driving tumor development and metastasis, the interactions between tumor cells and tumor microenvironment, and the similarities between canine and human melanoma, as well as melanoma from other species, will be also considered for publication in this Research Topic issue, since they represent an important basis for the comparative oncology approach.
We therefore welcome all types of articles that are focused on the main aspects of this tumor including:
• Cytology;
• Histopathology and clonality tests;
• Flow cytometry;
• Tumor staging;
• Biomarkers;
• Diagnostic imaging;
• Conventional treatments,
• Radiotherapy;
• Surgery;
• Immunotherapy;
• Novel therapy;
• Genetics and genomics;
• Animal model
dr. Philip Bergman receives minority royalty payments from BI Animal Health for the Oncept melanoma vaccine as he is on the xenogeneic DNA patent with co-investigators at MSKCC.
Canine and human melanoma share numerous biological and molecular features. In both species, malignant melanoma (MM) is a highly aggressive tumor of skin and mucosae. Similar to human MM, canine MM is often associated with an aggressive malignant behavior with rapid invasion of surrounding normal tissues, frequent metastasis and resistance to therapy. Despite numerous advances in the diagnostic and treatment options, MM remains fatal in most of the cases. For this reason, there is currently an urgent need to better understand genetic and molecular mechanisms driving melanoma development and progression, as well as find valuable new prognostic biomarkers, and novel, effective therapeutic approaches to improve rate of patient survival.
Submissions that focus on new melanoma diagnosis measures, able to allow an early detection of the tumor, helping in the distinction between benign and malignant cases, recognition of metastatic patients, are highly encouraged. In addition, results on treatment of canine melanoma with new therapeutic approaches exploiting immune- or targeted therapy are welcomed. Finally, studies shedding light on the molecular and biological pathways driving tumor development and metastasis, the interactions between tumor cells and tumor microenvironment, and the similarities between canine and human melanoma, as well as melanoma from other species, will be also considered for publication in this Research Topic issue, since they represent an important basis for the comparative oncology approach.
We therefore welcome all types of articles that are focused on the main aspects of this tumor including:
• Cytology;
• Histopathology and clonality tests;
• Flow cytometry;
• Tumor staging;
• Biomarkers;
• Diagnostic imaging;
• Conventional treatments,
• Radiotherapy;
• Surgery;
• Immunotherapy;
• Novel therapy;
• Genetics and genomics;
• Animal model
dr. Philip Bergman receives minority royalty payments from BI Animal Health for the Oncept melanoma vaccine as he is on the xenogeneic DNA patent with co-investigators at MSKCC.
Keywords: Dog, Melanoma, Comparative Oncology, Diagnostics, Therapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
